This CME intends to provide an update on the use of biological therapies for rheumatoid arthritis during COVID-19 outbreak. It elucidates about recommendations from the Indian Rheumatology Association followed by the American College of Rheumatology and the Australian Rheumatology Association along with the NICE guidelines on the treatment considerations for biological therapies and other drugs. It also features the COVID-19 Global Rheumatology Alliance and the EULAR-COVID-19 Database. Lastly, it highlights the interaction between SARS-CoV2 with S/B DMARDs and the use of tocilizumab with reference to COVID-19.
